Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Cancer-Related Exclusion Criteria:
Ocular Exclusion Criteria:
Cardiac Exclusion Criteria:
Central Nervous System (CNS) Exclusion Criteria:
Additional Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
514 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal